INCB052793

DRUG2 trials

Sponsors

Incyte Corporation

Conditions

Advanced MalignanciesMetastatic CancerSolid Tumors

Phase 1

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

TerminatedNCT02265510

Incyte CorporationAdvanced Malignancies, Metastatic Cancer, Solid Tumors

Start: 2014-09-10End: 2019-02-27Updated: 2020-04-17

Unknown Phase

Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis

Incyte Corporation

Updated: 2019-04-08